This core will function as a shared resource representing about 25% of the activity of the Gene Therapy Vector Production Laboratory which is part of the Baylor College of Medicine Center for Gene Therapy. The purpose of the core will be to enable the production of gene therapy vectors for testing in human clinical trials. A core is necessary for this function due to the high cost of the infrastructure and expertise necessary to satisfy FDA requirements for the approval of biologicals in clinical trials. The physical characteristics of the facility will help assure sterile vector production. These include seamless flooring, epoxy resin wall and ceiling covering, positive pressure air flow HEPA filtered air, HEPA filtered biosafety hoods, certified equipment and a gowning/airlock secured double door entrance room. All equipment and supplies used at the facility will be approved for the production of biologicals used in human trials. This includes certification by the suppliers, quality assurance by the facility, and standard operating procedures (SOPs) for the receipt, inventory, expiration and disposal of all material. All operations and procedures in the laboratory will be governed by SOPs approved by the Center for Biologics Evaluation and Review (CBER). Personnel involved in the production of vectors will be trained in Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) as required by statute. The Core will be responsible for the production of master cell banks and working cell banks necessary for the production of the vectors at sufficient scale under controlled conditions to allow their use in Phase I clinical trials. Adenovirus vectors will be grown in the helper human cell line 293. The Gene Therapy Vector Production Laboratory will also produce master cell banks for retroviral packaging cell lines, although this will only be a small component of the activities for this Program Project. The Core will be responsible for rigorous quality control to ensure the safety of the materials that will be administered to the patients and to ensure the safety of the personnel involved in the production of the vectors. This will involve detailed record keeping, in- house quality assurance and the oversight of subcontracted quality control tests. The operational director of the laboratory will be responsible for personnel training and compliance with FDA requirements. He has scientific interests in viral vector development and has been trained in the procedural requirements for production of biologicals for the enactment of investigational new drug (IND) applications. He will be an important resource for all independent investigators initiating clinical protocols, as a consultant in the early phases of the project and in the preparation and presentation of materials to the NIH Recombinant DNA Advisory Committee and FDA.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051754-04
Application #
5214121
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1996
Total Cost
Indirect Cost
Sakuma, Tsutomu; Gu, Xiu; Wang, Zheng et al. (2006) Stimulation of alveolar epithelial fluid clearance in human lungs by exogenous epinephrine. Crit Care Med 34:676-81
Toietta, Gabriele; Mane, Viraj P; Norona, Wilma S et al. (2005) Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 102:3930-5
Pastore, Lucio; Belalcazar, L Maria; Oka, Kazuhiro et al. (2004) Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 327:153-60
Morral, Nuria; O'Neal, Wanda K; Rice, Karen et al. (2002) Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 13:143-54
Toietta, Gabriele; Pastore, Lucio; Cerullo, Vincenzo et al. (2002) Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5:204-10
O'Neal, W K; Zhou, H; Morral, N et al. (2000) Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 6:179-95
Morral, N; O'Neal, W; Rice, K et al. (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 96:12816-21
Lee, B; Dennis, J A; Healy, P J et al. (1999) Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia. Proc Natl Acad Sci U S A 96:3981-6
O'Neal, W K; Zhou, H; Morral, N et al. (1998) Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum Gene Ther 9:1587-98
Morral, N; Parks, R J; Zhou, H et al. (1998) High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 9:2709-16

Showing the most recent 10 out of 25 publications